Rani Therapeutics Holdings, Inc. filed a Form D with the Securities and Exchange Commission on 2025-11-10.
Rani Therapeutics Holdings, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 10, 2025. The filing reports $60.26M sold. Its industry group is Biotechnology. It names Talat Imran (Executive Officer, Director), Svai Sanford (Executive Officer), Mir Imran (Director) (SEC Form D, November 10, 2025).
Is this your company?
Sell to companies like Rani Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Rani Therapeutics Holdings, Inc.
Free to see. No signup.
More on the people and the money behind Rani Therapeutics Holdings, Inc., from the filings we hold.
H.C. Wainwright & Co, LLC received sales compensation on this raise and on 19 other raises we hold, nearest in date first:
Maxim Group LLC received sales compensation on this raise and on 16 other raises we hold, nearest in date first:
Biotechnology raises by companies based in California, filed in November 2025, largest first.
Get an email when Rani Therapeutics Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Rani Therapeutics Holdings, Inc. raises, hires or launches. No email unless you switch it on.
Watch Rani Therapeutics Holdings, Inc. →Get the full cited report on Rani Therapeutics Holdings, Inc.
What the filing shows about Rani Therapeutics Holdings, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Rani Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Rani Therapeutics Holdings, Inc.'s address as 2051 Ringwood Avenue, San Jose, CA 95131.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Rani Therapeutics Holdings, Inc. See pricing
Rani Therapeutics Holdings, Inc. is a registered filer with the SEC (CIK 1856725) and has filed since 2025-11-10. 1 filing is on record, the latest on 2025-11-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Rani Therapeutics Holdings, Inc.'s Form D of 2025-11-10 names Talat Imran, Svai Sanford, Mir Imran and 6 more as its officers, directors or promoters.
Its new offerings report $60.26M sold across 1 offering, as its own filings state.
Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $60.26M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Talat Imran is named as Executive Officer and Director on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Svai Sanford is named as Executive Officer on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Mir Imran is named as Director on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Dennis Ausiello is named as Director on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Jean-Luc Butel is named as Director on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Mir Hashim is named as Executive Officer on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Lisa Rometty is named as Director on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Abraham Bassan is named as Director on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
Vasudev Bailey, M.D. is named as Director on the Form D that Rani Therapeutics Holdings, Inc. filed with the SEC on 10 November 2025, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2025-11-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Rani Therapeutics Holdings, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Rani Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rani Therapeutics Holdings, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Rani Therapeutics Holdings, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Rani Therapeutics Holdings, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Rani Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/rani-therapeutics-holdings-inc-form-d-25000001